LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Medtronic PLC

Geschlossen

BrancheGesundheitswesen

87.41 0.59

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

86.78

Max

87.43

Schlüsselkennzahlen

By Trading Economics

Einkommen

16M

1.3B

Verkäufe

-111M

8.3B

KGV

Branchendurchschnitt

23.197

51.198

EPS

1.62

Dividendenrendite

3.39

Gewinnspanne

15.605

Angestellte

95,000

EBITDA

-42M

2.4B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+10.07% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.39%

2.40%

Nächstes Ergebnis

19. Aug. 2025

Nächste Dividendenausschüttung

11. Juli 2025

Nächstes Ex-Dividendendatum

27. Juni 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-13B

107B

Vorheriger Eröffnungskurs

86.82

Vorheriger Schlusskurs

87.41

Nachrichtenstimmung

By Acuity

26%

74%

68 / 380 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bearish Evidence

Medtronic PLC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

21. Mai 2025, 11:38 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Medtronic Boosts Dividend, Plans to Separate Diabetes Business and Targets Revenue Growth for Year

18. Feb. 2025, 12:24 UTC

Ergebnisse

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

21. Mai 2025, 17:23 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Medtronic to Separate Diabetes Business as Stand-Alone Company -- 2nd Update

21. Mai 2025, 11:39 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Medtronic to Separate Diabetes Business as Stand-Alone Company -- Update

21. Mai 2025, 10:52 UTC

Ergebnisse

Medtronic Sees FY26 Adjusted EPS Up About 4% Excluding Potential Impacts From Increased Tariffs >MDT

21. Mai 2025, 10:51 UTC

Ergebnisse

Medtronic Sees FY26 Adj EPS $5.50-Adj EPS $5.60, Including Potential Tariff Impact >MDT

21. Mai 2025, 10:50 UTC

Ergebnisse

Medtronic Sees FY26 Reported Revenue Up 4.8%-5.1% if Recent Forex Rates Hold >MDT

21. Mai 2025, 10:49 UTC

Ergebnisse

Medtronic Sees FY26 Organic Revenue Growth Up About 5% >MDT

21. Mai 2025, 10:49 UTC

Ergebnisse

Medtronic Names Michael Carter Sr VP, President of Cranial, Spinal Technologies >MDT

21. Mai 2025, 10:48 UTC

Ergebnisse

Medtronic Names Skip Kiil Exec VP, President of Cardiovascular Portfolio >MDT

21. Mai 2025, 10:48 UTC

Ergebnisse

Medtronic: Sean Salmon, Exec VP and President of, Cardiovascular Portfolio Leaving >MDT

21. Mai 2025, 10:47 UTC

Ergebnisse

Medtronic Raises Quarterly Dividend to 71c From 70c >MDT

21. Mai 2025, 10:45 UTC

Akquisitionen, Fusionen, Übernahmen

Medtronic: Preferred Path of Initial Public Offering, Subsequent Split-Off >MDT

21. Mai 2025, 10:45 UTC

Ergebnisse

Medtronic Reports Strong Finish To Its Fiscal Year With Its Fourth Quarter Financial Results; Announces Dividend Increase >MDT

21. Mai 2025, 10:45 UTC

Ergebnisse

Medtronic 4Q Net $1.06B >MDT

21. Mai 2025, 10:45 UTC

Ergebnisse

Medtronic 4Q Medical Surgical Portfolio Rev $2.21B >MDT

21. Mai 2025, 10:45 UTC

Ergebnisse

Medtronic 4Q Neuroscience Portfolio Rev $2.62B >MDT

21. Mai 2025, 10:45 UTC

Ergebnisse

Medtronic 4Q Diabetes Rev $728M >MDT

21. Mai 2025, 10:45 UTC

Ergebnisse

Medtronic 4Q Organic Revenue Up 5.4% >MDT

21. Mai 2025, 10:45 UTC

Ergebnisse

Medtronic 4Q Adj EPS $1.62 >MDT

21. Mai 2025, 10:45 UTC

Ergebnisse

Medtronic 4Q EPS 82c >MDT

21. Mai 2025, 10:45 UTC

Ergebnisse

Medtronic 4Q Cardiovascular Portfolio Rev $3.34B >MDT

21. Mai 2025, 10:45 UTC

Ergebnisse

Medtronic 4Q Sales $8.93B >MDT

21. Mai 2025, 09:00 UTC

Top News
Akquisitionen, Fusionen, Übernahmen

Medtronic to Separate Diabetes Business as Stand-Alone Company -- WSJ

21. Mai 2025, 09:00 UTC

Akquisitionen, Fusionen, Übernahmen

Medtronic to Separate Diabetes Business, Sources Say -- WSJ

21. Mai 2025, 09:00 UTC

Akquisitionen, Fusionen, Übernahmen

Medtronic's Separation of Diabetes Business to Finish Within 18 Months, Sources Say -- WSJ

21. Mai 2025, 09:00 UTC

Akquisitionen, Fusionen, Übernahmen

Medtronic Diabetes Business Sales Totaled Nearly $2.5B in 2024 -- WSJ

27. Feb. 2025, 10:30 UTC

Top News

Squeezed by Strong Dollar, Companies Try to Neutralize Currency Swings -- WSJ

18. Feb. 2025, 11:47 UTC

Ergebnisse

Medtronic: Will Accelerate Top-, Bottom-Line Growth in 4Q >MDT

18. Feb. 2025, 11:46 UTC

Ergebnisse

Medtronic Still Sees FY25 Organic Revenue Growth 4.75%-5% >MDT

Peer-Vergleich

Kursveränderung

Medtronic PLC Prognose

Kursziel

By TipRanks

10.07% Vorteil

12-Monats-Prognose

Durchschnitt 95.76 USD  10.07%

Hoch 109 USD

Tief 87 USD

Basierend auf 21 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Medtronic PLC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

21 ratings

11

Buy

10

Halten

0

Sell

Technischer Score

By Trading Central

83.26 / 84.875Unterstützung & Widerstand

Kurzfristig

Weak Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

68 / 380 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Medtronic PLC

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.